IgE/antigen-mediated enhancement of IgE production is a mechanism underlying the exacerbation of airway inflammation and remodelling in mice

Immunology

Volumn 144, Issue 1, 2015, Pages 107-115

  Mizutani, Nobuaki ^a   Nabe, Takeshi ^b,c   Yoshino, Shin ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

Airway hyper responsiveness; Asthma; Biphasic increase in airway resistance; IgE; Inflammation; Remodelling

Indexed keywords

ANTIGEN; ANTIGEN ANTIBODY COMPLEX; CYTOKINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OVALBUMIN;

AIRWAY REMODELING; ANIMAL; ANTIGEN ANTIBODY COMPLEX; ASTHMA; BAGG ALBINO MOUSE; DRUG EFFECTS; IMMUNOLOGY; LUNG; MALE; MOUSE; PATHOLOGY;

AIRWAY REMODELING; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS; ASTHMA; CYTOKINES; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LUNG; MALE; MICE; MICE, INBRED BALB C; OVALBUMIN;

EID: 84918817597     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12355     Document Type: Article

References (33)

1. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789-815.
2. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
3. Pauwels R. The relationship between airway inflammation and bronchial hyperresponsiveness. Clin Exp Allergy 1989; 19:395-8.
4. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101:916-21.
5. Bousquet J, Chanez P, Lacoste JY et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033-9.
6. De Monchy JG, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, De Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985; 131:373-6.
7. Ebina M, Takahashi T, Chiba T, Motomiya M. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am Rev Respir Dis 1993; 148:720-6.
8. Hossain S, Heard BE. Hyperplasia of bronchial muscle in chronic bronchitis. J Pathol 1970; 101:171-84.
9. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145:890-9.
10. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 1:520-4.
11. Heyman B, Tianmin L, Gustavsson S. In vivo enhancement of the specific antibody response via the low-affinity receptor for IgE. Eur J Immunol 1993; 23:1739-42.
12. Gustavsson S, Hjulström S, Liu T, Heyman B. CD23/IgE-mediated regulation of the specific antibody response in vivo. J Immunol 1994; 152:4793-800.
13. + B cells. J Immunol 2005; 175:1473-82.
14. Mizutani N, Goshima H, Nabe T, Yoshino S. Establishment and characterization of a murine model for allergic asthma using allergen-specific IgE monoclonal antibody to study pathological roles of IgE. Immunol Lett 2012; 141:235-45.
15. Mizutani N, Nabe T, Yoshino S. Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology 2013; 139:205-18.
16. Mizutani N, Goshima H, Nabe T, Yoshino S. Complement C3a-induced IL-17 plays a critical role in an IgE-mediated late-phase asthmatic response and airway hyperresponsiveness via neutrophilic inflammation in mice. J Immunol 2012; 188:5694-705.
17. Mizutani N, Nabe T, Yoshino S. IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice. J Immunol 2014; 192:1372-84.
18. Mizutani N, Nabe T, Yoshino S. Complement C3a regulates late asthmatic response and airway hyperresponsiveness in mice. J Immunol 2009; 183:4039-46.
19. Haak-Frendscho M, Robbins K, Lyon R, Shields R, Hooley J, Schoenhoff M, Jardieu P. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 1994; 82:306-13.
20. Nabe T, Matsuya K, Akamizu K et al. Roles of basophils and mast cells infiltrating the lung by multiple antigen challenges in asthmatic responses of mice. Br J Pharmacol 2013; 169:462-76.
21. Denzel A, Maus UA, Rodriguez Gomez M et al. Basophils enhance immunological memory responses. Nat Immunol 2008; 9:733-42.
22. Pennock BE, Cox CP, Rogers RM, Cain WA, Wells JH. A noninvasive technique for measurement of changes in specific airway resistance. J Appl Physiol Respir Environ Exerc Physiol 1979; 46:399-406.
23. Oettgen HC, Geha RS. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999; 104:829-35.
24. Galli SJ. Mast cells and basophils. Curr Opin Hematol 2000; 7:32-9.
25. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23:749-86.
26. Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune responses. Blood 2000; 96:4028-38.
27. Schroeder JT, MacGlashan DW Jr, Lichtenstein LM. Human basophils: mediator release and cytokine production. Adv Immunol 2001; 77:93-122.
28. Voehringer D, Shinkai K, Locksley RM. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 2004; 20:267-77.
29. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 2014; 14:94-108.
30. Tkaczyk C, Okayama Y, Woolhiser MR, Hagaman DD, Gilfillan AM, Metcalfe DD. Activation of human mast cells through the high affinity IgG receptor. Mol Immunol 2002; 38:1289-93.
31. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-90.
32. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115:459-65.
33. Holgate ST, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-8.